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Expression of Lymphocyte Homing Receptor as a Mechanism of Dissemination in 
Non-Hodgkin’s Lymphoma
By Steven T. Pals, Eveliene Horst, Gert J. Ossekoppele, Carl G. Figdor, R.J. Scheper, and Chris J.L.M. Meijer
To investigate whether the lymphocyte homing receptor 
(LHR), an adhesion molecule believed to play an important 
role in the control of normal lymphocyte circulation, 
influences the spread of non-Hodgkin's lymphoma (NHL), 
expression of LHR was examined in 107 NHL of various 
histologic and immunophenotypic subclasses. This analysis 
revealed that whereas NHL with a putative derivation from 
recirculating mature T and B lymphocytes almost invariably 
express high levels of LHR, those akin to sessile mature or
A N IMPORTANT feature of mature lymphocytes is 
their ability to recirculate continuously between the 
lymphoid organs. This dynamic process is an essential com­
ponent of the functional immune system, providing a means 
for constant surveillance of the organism’s tissues by immu­
nocompetent cells.1'1 A central step in the physiology of 
lymphocyte recirculation is the migration of lymphocytes 
from the blood to the surrounding tissues through the wall of 
high endothelial venules (HEV). These specialized venules 
have a cuboid endothelial morphology and are present in the 
T-cell areas of lymphnodes and mucosa-associated lymphoid 
tissues (MALT) .1'3 Moreover, they can arise in a variety of 
chronic inflammatory conditions, including autoimmune 
thyroiditis, rheumatoid arthritis, and chronic inflammatory 
bowel disease.4'6
It is now clear that migration of lymphocytes through 
HEV involves specific recognition of and adhesion to their 
endothelial lining by lymphocyte homing receptors (LHR) 
expressed on the lymphocyte cell surface.3,5,7,8 In the mouse3,9 
and in man3,10 antibodies against these LHR define a related 
set of 90-Kd glycoproteins. The expression of LHR and, in 
parallel, the capacity of various lymphocyte populations to 
adhere to and migrate through HEV, depends on their state 
of maturation and activation.3,9,10,11 Thus, mature resting T 
and B lymphocytes, which belong to the recirculating lym­
phocyte pool, express high levels of LHR. In contrast, 
cortical thymocytes and germinal-center B cells are sessile 
ceils and generally are either LHR negative or low.3,9,10
In view of the concept that NHL present the malignant 
counterparts of normal lymphocytes “frozen” at a certain 
stage of maturation/activation, it is conceivable that the 
same mechanisms regulating normal lymphocyte traffic are, 
at least to a certain extent, operating in lymphoid malignan­
cies. If so, the ‘‘homing phenotype” of NHLs would be 
expected to influence the spread of these neoplasms. This 
possibility is supported by the finding that homing receptor 
expression in transplantable murine lymphomas correlates 
with their capacity to give rise to generalized lymph node 
dissemination on passage to syngeneic recipients.12 In the 
present paper the authors have investigated the expression of 
LHR by human NHL of various types and have correlated 
these findings to the clinical stage.
MATERIALS AND METHODS
Case selection and classification. A panel of N H L  of various 
histologic and immunophenotypic subclasses was selected from the 
material collected at the Department of Pathology, Free University
immature lymphocytes tend to express lower levels of 
LHR. Furthermore, in a survey among diffuse large-cell 
lymphomas of the B-lineage, the tumors of 11 of 13 
patients with stage III/IV  disease expressed moderate to 
high levels of LHR, whereas only two of 17 patients with 
stage i/ll  disease had tumors that did so. These findings 
suggest that LHR is involved in the dissemination of NHL.
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Hospital, Amsterdam from 1985 to 1988 and tested for LHR- 
antigen expression employing the monoclonal antibodies (MoAbs) 
NKI-P1 and NKI-P2. Histologic subclassification of N H L was 
based on the International Working Formulation.13 By their staining 
patterns with pan-T and pan-B MoAbs the N H L were divided into 
B-lineage and T-lineage. A tumor was considered B-lineage if 
expression of one or more pan-B antigens was detected in the absence 
of T antigens and vice versa. Because of homogeneity for the features 
the authors examined, cases of small lymphocytic lymphoma with or 
without plasmacytoid differentiation were considered together in the 
category of small lymphocytic lymphoma. For similar reasons cases 
of follicular and follicular and diffuse small-cleaved, mixed, and 
large-cell lymphoma were considered together in the category of 
follicular lymphoma; diffuse large-cleaved cell, large noncleaved 
cell* and large cell with immunoblastic features (of the B-lineage) 
were considered together in the category of diffuse large-cell lym­
phoma.
MoAbs. The development and specificity of the hybridomas 
NKI-P1 and NKI-P2 will be described elsewhere (S.T, Pals, manu­
script in preparation), In brief, the MoAbs secreted by these 
hybridomas immunoprecipitate a major product with a mol wt of 90 
Kd from 1251-labeled human monocytes. This product was shown to 
be identical to the human LHR described by Jalkanen et al.10 
Functional studies using the MoAbs NK.I-P1 and NKI-P2 showed 
both MoAbs to inhibit the binding of human peripheral blood 
lymphocytes to HEV in vitro, indicating that they are directed 
against a functional epitope on the LHR. Immunoperoxidase stain­
ing was performed on aceton-fixed cryostat section by an indirect 
immunoperoxidase procedure, as described previously.6 NKI-P1 and 
NKI-P2 were employed as supernatant at concentrations to give 
optimal staining results. The second stage antibody, horseradish 
peroxidase-conjugated rabbit antimouse IgG (DAKO, Denmark) 
contained 5% normal human serum. Sections were routinely coun­
terstained with haematoxylin. Since cross-blocking studies indicated
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that NKI-P 1 and NKI-P2 recognize overlapping epitopes and since 
the staining results obtained with these MoAbs were virtually 
identical, they are considered together. Staining intensity was scored 
semiquantitatively on a scale of 0 to 3 (0, negative; 1, weak; 2, 
moderate; 3, strong).
Clinical,staging procedures. Expression of LHR antigen, as 
defined by staining with NKI-P MoAbs, was correlated to clinical 
stage in 30 patients with diffuse large-cell lymphoma of the B- 
lineage who had undergone a complete staging procedure within 6 
weeks following the initial biopsy. The staging procedure routinely 
included thorough physical examination, blood profile and buffycoat 
examination, rhinolaryngoscopy, chest and abdominal X-rays, a 
variable combination of abdominal/pelvic computerized tomogra­
phy (CT), lymphangiography and echography, and bone marrow 
smears and biopsies. Results were classified according to the Ann 
Arbor staging system.14 For statistical evaluation of staging results 
the chi-square test was used.
RESULTS
LHR expression in non-Hodgkin’s lymphoma. In accor­
dance with other reports describing the distribution of LHR 
in normal and reactive lymphoid tissues,3,9,10 the authors 
observed a high expression of the antigens recognized by 
NKI-P 1 /2  on most cells of both the B-lineage and T-lineage 
as well as on macrophages/dendritic cells. B lymphocytes in 
primary follicles, mantle zones, and interfollicular areas and 
T lymphocytes in the interfollicular and paracortical areas of 
the lymphoid tissues were strongly NKI-P1/2 positive (2 to 
3+). Plasma cells were also positive. In contrast, germinal 
center B cells were weak to negative (0 to 1 + ). Similarly the 
vast majority of cortical thymocytes lacked LHR antigen 
expression (0).
The various subtypes of NHL were heterogeneous with 
respect to LHR antigen expression (Table 1). Diffuse small­
cell lymphomas/leukemias of the B-lineage were all strongly 
NKI-P 1/2 positive (2 to 3+). The intensity of staining in 
these lymphomas was similar to that observed in normal 
primary follicLes and mantle zones. The plasma cell tumors 
also showed uniform LHR antigen expression. Similarly, all
Table 1. Lymphocyte Homing Receptor Expression in
Non-Hodgkin's Lymphoma
Subtype
No. NKI-P4- Staining Intensity 
Range*
.......  1/0/
No. tested
B-cell lymphoma
Diffuse small-cell 24/24 ( 100) 2-3 +
small lymphocytic 20/20 {100) 2-3 +
small cleaved 4/4  (100) 2-3 +
Diffuse large-cell 30/36 (80) 0-3 +
Follicular 4/8 (50)f 0-3 +
Burkitt 0/3 (0) 0
Myeloma/plasm ocytoma 3/3 (100) 2-3 +
T-cell lymphoma
Peripheral 29/29 (100) 2-3 +
Mycosis Fungoides (MF) 12/12  (100) 2-3 +
Non-MF 17/17 ( 100) 2-3 +
Lymphoblastic 2/4  (50) 0-2 +
*0, negative; 1 +  , weak; 2 + , moderate; 34-, strong.
j-lmportant intratumor NKI-P expression heterogeneity with a variable 
population of strongly positive tumor cells at the periphery of the 
malignant follicles.
peripheral T-cell lymphomas, regardless of their histologic 
type, stained intensively with the NKI-P antibodies and in 
this respect were comparable to normal mature T cells (2 to 
3 + ).
In contrast to the strong LHR antigen expression in the 
above-mentioned NHL, those subtypes of NHL with charac­
teristics of germinal center B cells, including follicular 
lymphoma and diffuse large-cell lymphoma» showed a highly 
variable LHR antigen expression. In follicular lymphoma 
LHR antigen-expressing tumor cells were either not detect­
able (50% of cases) or presented a subpopulation of tumor 
cells with a relatively high-staining intensity that tended to 
be localized at the periphery of the malignant follicles. By 
their staining pattern these lymphomas thus resembled reac­
tive germinal centers. Similarly, approximately half of the 
diffuse large-cell lymphomas of the B-lineage either failed to 
express detectable LHR antigen or showed only weak expres­
sion. Interestingly, the other half of the lymphomas in this 
category showed a homogeneous expression of moderate- 
to-high levels of LHR antigen (2 to 3 -I-). These differences in 
expression were not related to the histologic subtype of 
diffuse large-cell lymphoma (data not shown).
Among the limited number of cases of Burkitt’s and 
lymphoblastic lymphoma tested LHR antigen expression 
was generally low or absent, a finding that is consistent with 
their immature character.
LHR expression and clinical stage. To test the hypothe­
sis that LHR expression plays a role in the dissemination of 
NHL, the authors compared the expression of LHR antigen 
with clinical stage in all patients with diffuse large-cell 
lymphoma for whom complete staging reports were avail­
able. The authors selected this subtype of lymphoma because 
it represented the largest subgroup in their series and, more 
importantly, because it was heterogeneous with respect to 
both LHR expression and clinical stage at presentation 
(Table 1).
As is shown in Fig 1, LHR expression by diffuse large-cell 
lymphomas of the B-lineage was clearly correlated to clinical 
stage: whereas 85% of stage III and IV lymphomas expressed 
LHR at moderate to high levels (2 to 3 + ), this relatively 
high-staining intensity was present in only 12% of the NHL 
in clinical stage I and II, the majority of lymphomas in the 
latter groups being 0 to 1 + (Fig 1). This difference between 
LHR expression in stage I and II v III and IV was highly 
significant (chi-square = 15.9, P < .001).
DISCUSSION
The cellular and molecular interactions involved in metas­
tasis are undoubtedly complex, but the adhesive properties of 
tumor cells are likely to play a key role in this process.15,16 
Although, because of their motility, lymphocytes may some­
times be thought of as nonadhesive cells, this is incorrect: 
Cell-cell adhesion is involved in almost every step during an 
immune response,17 and the fact that lymphocytes may 
recirculate through blood and lymph appears to result from 
their ability to regulate their adhesive properties, including 
their LHR receptor expression, continuously.3,9,10’11,17,18
The marked heterogeneity in LHR expression among 
NHL of various subclasses in the authors’ present study
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Fig 1. Expression of LHR antigen in diffuse large-cell lym­
phoma of the B-lineage in relation to clinical stage (Ann Arbor). 
85% of stage III and IV lymphomas are LHR 2  to 3 +  v only 12% of 
NHL in stage I and II [P <  .001).
probably reflects these regulatory processes, since it parallels 
the maturation and activation-dependent expression patterns 
on (putatively) related compartments of the normal lym­
phoid system. Thus, whereas NHL akin to peripheral T cells 
or small, resting B cells, like these benign counterparts, were 
found to express high levels of LHR, NH L related to 
germinal center cells or immature lymphoid precursors 
tended to show a much lower LHR expression (Table 1). 
Importantly, however, this parallel between LHR expression 
in reactive lymphoid tissues and their malignant counter­
parts was far from complete. Particularly in the group of 
diffuse large-cell lymphomas of the B-lineage, consisting 
largely of neoplasms related to large germinal center cells, 
the LHR expression was widely variable, ranging from 0 to 
3 + (Table 1).
The central finding of this study is the significant correla­
tion (P < .001) between LHR expression and clinical stage 
in diffuse large-cell lymphoma of the B-lineage; thus high 
expression of LHR was correlated to stage III/IV disease, 
while lymphomas exhibiting limited spread were generally 
LHR low or negative. In combination with current data 
concerning the role of LHR in the biology of lymphocyte 
traffic, the authors’ findings strongly suggest that LHR 
plays a role in the dissemination of these NHL.
It should be noted, however, that the correlation beween 
LHR expression and disease stage is incomplete, given that 
the authors observed wide lymphoma dissemination in some 
cases without LHR expression. This indicates that LHR
expression is not an absolute requirement for tumor spread. 
Several factors might explain this observation. First, mole­
cules other than LHR are likely to be involved in lymphoma 
dissemination. Pertinent to this point are observations by the 
authors and others indicating that in addition to LHR, 
LFA-1 is also involved in lymphocyte migration through 
HEV.19,20 Second, factors other than adhesiveness are likely 
to play a role in lymphoma dissemination. These may include 
changes in cytoskeletal structure influencing migratory 
capacity, differences in growth character, etc.
The authors’ conclusion that LHR is likely to play a role in 
the dissemination of NHL is corroborated by the characteris­
tic dissemination and LHR expression patterns of most of the 
other NHL subcategories, For example, diffuse small-cell 
lymphoma, a NHL category with strong LHR expression, 
almost invariably presents at clinical stage IV.13 Similarly, 
peripheral T-cell lymphomas, which all express high levels of 
LHR, tend to disseminate widely.21 Follicular lymphomas 
present an obvious exception to this rule, since they show a 
low LHR antigen expression but are mostly widely dissemi­
nated at the time of diagnosis.13 This might be explained, 
however, by the finding of strongly LHR antigen-positive 
tumor cells at the periphery of the malignant follicles in a 
significant proportion of these lymphomas.22 It is conceivable 
that these cells comprise the malignant counterparts of early 
recirculating memory B cells developing from sessile germi­
nal center cells and consequently have a large potency to 
disseminate.
The general distribution pattern of LHR antigen among 
NHL of various histologic and immunophenotypic subcate­
gories in the authors’ present study resembles the distribu­
tion pattern recently described by Picker et al.22 These 
authors, however, could not demonstrate a significant corre­
lation between LHR expression and clinical stage, although 
a weak nonsignificant association was observed, Althou 
the authors cannot at present explain this discrepancy, it is 
conceivable that differences in the fine specificity of the 
MoAbs used in both studies play a role, since the authors’ 
results indicate that NK1-P1/2 recognizes a different 
domain on the LHR than Hermes-3 (used by Picker et al22; 
S.T. Pals, manuscript in preparation10).
In conclusion, although the findings presented here cannot 
definitively prove that LHR is involved in the dissemination 
of NHL, it is tempting to speculate that high LHR expres­
sion in large-cell lymphomas, which correlates with wide 
dissemination, is an important factor in tumor spread.
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